Explainer-What is the impact of Philips' recall of sleep apnea devices?
Send a link to a friend
[August 22, 2022]
By Julie Steenhuysen
CHICAGO (Reuters) - A massive recall of
Philips breathing devices in 2021 due to a risk of potential injury has
left physicians scrambling to find alternatives for the growing number
of people who use them.
Philips said last week it is about halfway through replacing the 5.5
million devices, which include mechanical ventilators as well as
non-invasive breathing devices used to treat sleep apnea, a condition
marked by brief pauses in breathing during sleep. The company recently
named a new chief executive, Roy Jakobs, to lead it through the recall.
Here is a summary of the recall's impact.
HOW COMMON IS SLEEP APNEA?
More than 30 million people in the United States suffer from sleep
apnea, but only a fraction are being treated, said Dr. Raj Dasgupta, a
sleep expert at the University of Southern California.
One major risk factor is obesity, and as obesity rates have climbed
worldwide so have the number of people who need continuous positive
airway pressure (CPAP) machines, which pump air through a face mask and
hose to ensure normal breathing.
The global market for treatments last year was $8 billion and is
expected to top $13 billion in 2028, according to market research firm
Fortune Business Insights.
In many sleep apnea patients, muscles in the back of the throat relax
during sleep, blocking the airway and causing a brief pause in
breathing. As blood oxygen drops, the stress hormone adrenaline causes
people to rouse and gasp for air.
For some, this happens hundreds of times a night, said Dr. Indira
Gurubhagavatula, a sleep medicine specialist at the University of
Pennsylvania Sleep Center in Philadelphia.
Recurrent drops in oxygen can cause high blood pressure, heart rhythm
problems, heart attacks and heart failure, as well as depression, memory
loss and trouble concentrating.
Sleep deprivation is also a risk.
"We worry about motor vehicle accidents, we worry about work-related
injuries because of the excessive sleepiness," Dasgupta said.
DETAILS OF THE RECALL
Dutch medical equipment company Philips initiated the recall in June
2021 for an estimated 3 million to 4 million devices. It increased that
number to 5.5 million devices on Aug. 17.
[to top of second column]
|
Dutch technology company Philips' logo
is seen at company headquarters in Amsterdam, Netherlands, January
29, 2019. REUTERS/Eva Plevier/File Photo
The recall involved devices using
sound abatement foam called PE-PUR, which the company said could
degrade into particles and be ingested or inhaled by the user. The
foam could also off-gas volatile organic chemicals.
The company has been replacing the insulation on
recalled devices with silicone foam, and expects to be done by
December 2022.
Since April 2021, the U.S. Food and Drug Administration (FDA) said
it has received more than 69,000 reports of malfunctions or injuries
associated with the PE-PUR foam breakdown, or suspected breakdown,
including 168 deaths. The reports do not prove that the devices are
directly responsible for injuries or deaths, but are used by the FDA
to track potential problems.
SCRAMBLING FOR SLEEP APNEA TREATMENTS
Several doctors said they received little warning of the recall or
guidance on keeping patients on a potentially faulty device until a
replacement became available. Their practices were deluged with
calls from patients worried their breathing machines were putting
them at risk for cancer.
“Digging our way out of all of this has been an incredible
challenge," Gurubhagavatula said, noting that competitor ResMed Inc
has struggled to meet the spike in demand.
Information on the cancer risk has been limited, said Dr. Justin
Fiala, a sleep medicine expert at Northwestern University's Feinberg
School of Medicine in Chicago.
He and other doctors have recommended their most critical patients
keep using their CPAP devices as they await a replacement.
Alternatives for less critical patients include using special
pillows to keep them from sleeping on their backs, over-the-counter
nasal strips to keep airways open and the recommendation to stop
drinking alcohol.
(Reporting by Julie Steenhuysen in Chicago; Additional reporting by
Ahmed Aboulenein in Washington; Editing by Josie Kao)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|